Literature DB >> 28843869

Development of a radioligand for imaging V1a vasopressin receptors with PET.

Ravi Naik1, Heather Valentine1, Andrew Hall1, William B Mathews1, James C Harris1, C Sue Carter2, Robert F Dannals1, Dean F Wong1, Andrew G Horti3.   

Abstract

A series of vasopressin receptor V1a ligands have been synthesized for positron emission tomography (PET) imaging. The lead compound (1S,5R)-1 ((4-(1H-indol-3-yl)-3-methoxyphenyl) ((1S,5R)-1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-yl)methanone) and its F-ethyl analog 6c exhibited the best combination of high binding affinity and optimal lipophilicity within the series. (1S,5R)-1 was radiolabeled with 11C for PET studies. [11CH3](1S,5R)-1 readily entered the mouse (4.7% ID/g tissue) and prairie vole brains (∼2% ID/g tissue) and specifically (30-34%) labeled V1a receptor. The common animal anesthetic Propofol significantly blocked the brain uptake of [11CH3](1S,5R)-1 in the mouse brain, whereas anesthetics Ketamine and Saffan increased the uptake variability. Future PET imaging studies with V1a radiotracers in non-human primates should be performed in awake animals or using anesthetics that do not affect the V1a receptor.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Positron emission tomography; Radiotracers; Vasopressin receptor

Mesh:

Substances:

Year:  2017        PMID: 28843869      PMCID: PMC6583924          DOI: 10.1016/j.ejmech.2017.08.037

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  37 in total

1.  Localization of vasopressin (V1a) receptor binding and mRNA in the rhesus monkey brain.

Authors:  L J Young; D Toloczko; T R Insel
Journal:  J Neuroendocrinol       Date:  1999-04       Impact factor: 3.627

Review 2.  Neuroactive steroids and anxiety disorders.

Authors:  Jean-Michel Le Mellédo; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2002-05       Impact factor: 6.186

Review 3.  Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication.

Authors:  Rainer Landgraf; Inga D Neumann
Journal:  Front Neuroendocrinol       Date:  2004 Sep-Dec       Impact factor: 8.606

Review 4.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents.

Authors:  Rikki N Waterhouse
Journal:  Mol Imaging Biol       Date:  2003 Nov-Dec       Impact factor: 3.488

5.  Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain. An autoradiographic study.

Authors:  F Loup; E Tribollet; M Dubois-Dauphin; J J Dreifuss
Journal:  Brain Res       Date:  1991-08-02       Impact factor: 3.252

6.  Effect of vasopressin administration and deficiency upon 3H-AVP binding sites in the CNS and periphery during development.

Authors:  P Szot; K M Myers; D M Dorsa
Journal:  Peptides       Date:  1992 Mar-Apr       Impact factor: 3.750

7.  Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills.

Authors:  N Yirmiya; C Rosenberg; S Levi; S Salomon; C Shulman; L Nemanov; C Dina; R P Ebstein
Journal:  Mol Psychiatry       Date:  2006-05       Impact factor: 15.992

8.  Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat.

Authors:  Kodai Tanaka; Michio Suzuki; Tomiki Sumiyoshi; Masahiko Murata; Masahiko Tsunoda; Masayoshi Kurachi
Journal:  Brain Res       Date:  2003-12-05       Impact factor: 3.252

9.  V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze.

Authors:  Nobuaki Egashira; Akito Tanoue; Fuminori Higashihara; Kenichi Mishima; Yoshihiko Fukue; Yukio Takano; Gozoh Tsujimoto; Katsunori Iwasaki; Michihiro Fujiwara
Journal:  Neurosci Lett       Date:  2004-02-19       Impact factor: 3.046

10.  Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice.

Authors:  Isadora F Bielsky; Shuang-Bao Hu; Kathleen L Szegda; Heiner Westphal; Larry J Young
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

View more
  2 in total

1.  Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging.

Authors:  Ahmed Haider; Zhiwei Xiao; Xiaotian Xia; Jiahui Chen; Richard S Van; Shi Kuang; Chunyu Zhao; Jian Rong; Tuo Shao; Perla Ramesh; Appu Aravind; Yihan Shao; Chongzhao Ran; Larry J Young; Steven H Liang
Journal:  Pharmacol Res       Date:  2021-09-16       Impact factor: 7.658

Review 2.  Positron Emission Tomography in the Neuroimaging of Autism Spectrum Disorder: A Review.

Authors:  Zhiqiang Tan; Huiyi Wei; Xiubao Song; Wangxiang Mai; Jiajian Yan; Weijian Ye; Xueying Ling; Lu Hou; Shaojuan Zhang; Sen Yan; Hao Xu; Lu Wang
Journal:  Front Neurosci       Date:  2022-04-13       Impact factor: 5.152

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.